Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
(Values in U.S. thousands)
| 09-2025 | 07-2025 | 04-2025 | 01-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -158,914 | -60,096 | N/A | -131,218 | N/A |
| Depreciation Amortization | 889 | 245 | N/A | 691 | N/A |
| Accounts receivable | -5,779 | -1,926 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 6,093 | 2,510 | N/A | -3,579 | N/A |
| Other Working Capital | 14,407 | -4,699 | N/A | 3,496 | N/A |
| Other Operating Activity | 16,319 | 9,464 | 0 | 18,067 | 0 |
| Operating Cash Flow | $-126,985 | $-54,502 | $N/A | $-112,543 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,245 | -437 | N/A | -414 | N/A |
| Purchase Of Investment | -105,772 | -19,979 | N/A | -7,547 | N/A |
| Sale Of Investment | 127,889 | 41,677 | N/A | 102,313 | N/A |
| Investing Cash Flow | $19,872 | $21,261 | $N/A | $94,352 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 139,438 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 3,693 | 1,289 | N/A | 59,838 | N/A |
| Other Financing Activity | 21,259 | 21,921 | 0 | 95,230 | 0 |
| Financing Cash Flow | $164,390 | $23,210 | $N/A | $155,068 | $N/A |
| Exchange Rate Effect | 4,042 | 2,723 | N/A | -725 | N/A |
| Beginning Cash Position | 182,978 | 132,272 | N/A | 31,789 | N/A |
| End Cash Position | 244,297 | 124,964 | N/A | 167,941 | N/A |
| Net Cash Flow | $61,319 | $-7,308 | $N/A | $136,152 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -126,985 | -54,502 | N/A | -112,543 | N/A |
| Capital Expenditure | -2,257 | -437 | N/A | -414 | N/A |
| Free Cash Flow | -129,242 | -54,939 | 0 | -112,957 | 0 |